Weight, Body clinical trials at University of California Health
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
Main LAP01 study: The purpose is to evaluate the long-term pathologic weight changes associated with multi-year risperidone or aripiprazole therapy in 3 - <18-year-old children, who have varying durations of prior antipsychotic drug exposure from the start of study Month 0 (M0). This is critical because children appear to have greater vulnerability to antipsychotic-associated weight gain than adults, and obesity has significant effects on morbidity and mortality. An additional sub-study (registry sub-study) has been added via a protocol amendment. This registry sub-study is optional for participant and only participants who participating in the main part of the study are eligible if they were 6 to less than 18 years of age at the time of the M0 visit. Participants who consent to this registry sub-study will participate in yearly in-person visits and complete monthly assessments remotely over the course of three additional years from the time of their final visit of the main LAP01 study.